Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Other Accumulated Expenses (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Other Accumulated Expenses for 15 consecutive years, with $102.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 4.91% to $102.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $102.4 million, a 4.91% decrease, with the full-year FY2024 number at $104.6 million, down 3.1% from a year prior.
  • Other Accumulated Expenses was $102.4 million for Q3 2025 at Usana Health Sciences, down from $103.7 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $149.9 million in Q1 2021 to a low of $97.2 million in Q2 2024.
  • A 5-year average of $119.2 million and a median of $111.7 million in 2022 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: grew 23.8% in 2021, then decreased 19.95% in 2022.
  • Usana Health Sciences' Other Accumulated Expenses stood at $144.3 million in 2021, then decreased by 7.95% to $132.8 million in 2022, then fell by 18.67% to $108.0 million in 2023, then decreased by 3.1% to $104.6 million in 2024, then decreased by 2.1% to $102.4 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Other Accumulated Expenses are $102.4 million (Q3 2025), $103.7 million (Q2 2025), and $100.4 million (Q1 2025).